Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 12/20 | 0.46 |
| ▸ | RAB9A | P51151 | 11/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.40 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.40 |
| ▸ | CBFB | Q13951 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30190003 | 1.00 | PDK1 (0.60) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2176039 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL369133 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28604628 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL137507 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1761326 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2642887 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13310867 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15689525 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29390917 | 0.77 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| CN-116888099-A | Short peptide compound containing beta-amino ketone and application thereof | 福建广生中霖生物科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023116811-A1 | SHORT PEPTIDE COMPOUND CONTAINING β-AMINOKETONE AND USE THEREOF | 福建广生中霖生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-9708331-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016177862-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2016-11-10 | — | — | WO | disclosed |
| US-20160251359-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-09-01 | — | — | US | disclosed |
| US-9260452-B2 | Metabotrophic glutamate receptor 5 modulators and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2012035055-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-22 | — | — | WO | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2011110575-A1 | DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | PDK1 951/4885POLB 2406/4885NPC1 2194/4885 |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | PDK1 264/4885POLB 397/4885NPC1 2786/4885 |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PDK1 3666/4885POLB 3541/4885NPC1 100/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | PDK1 2802/4885POLB 3228/4885NPC1 2563/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | PDK1 504/4885POLB 2070/4885NPC1 1908/4885 |
| US-20160251359-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | PDK1 855/4885POLB 3003/4885NPC1 1920/4885 |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | PDK1 855/4885POLB 3003/4885NPC1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.